Optimising treatment (TDM)
Optimising treatment (Biomarkers)
Therapeutic Drug Monitoring (TDM) and biomarkers such as faecal calprotection (FC) can be useful tools in helping to support clinical decision making to optimsie treatment. Treatment optimisation can involve changing the dosing, infusion interval or stopping treatment.
Please note that Inflectra/infliximab is not licensed for dose escalation in ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, paediatric ulcerative colitis or paediatric Crohn's disease.
Faecal calprotectin (FC) is a biomarker of disease activity in IBD.
FC correlates with inflammatory activity in CD and UC.1
It is stable in stool for up to 3 days at room temperature so it is readily mesaurable.2
FC levels can be used to:
Learn how Infliximab works.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020